All In Biotech

Drug Trial Radar · NCT00377676

Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability During Treatment of Type 2 Diabetes (T2DM) With Usual Diabetes Therapy (UDT) and Either Cycloset or Placebo

Last checked: Nov 20, 2026Latest source record: Jun 10, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,095 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,095

Actual

Start

Jul 2004

Primary completion

Jan 2007

Study completion Jan 2007

Sponsor

Lead sponsor
VeroScienceIndustry
Sponsor type
Industry
First posted
Sep 18, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cycloset, a new quick-release oral formulation of bromocriptine mesylate, effectively reduces blood sugar by the proposed mechanism of reversing many of the metabolic alterations associated with insulin resistance and obesity by resetting central (hypothalamic) circadian organization of monoamine neuronal activities. The primary analysis of this study will test the hypothesis that the rate of all-cause severe adverse events for those receiving usual drug therapy for diabetes management plus Cycloset is not greater than that for usual drug therapy plus placebo by more than an acceptable margin. While the primary purpose of this study is to establish the safety profile of Cycloset in type 2 diabetes, any potential positive cardiovascular benefits will be evaluated as well.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • CyclosetDrug

    Usual diabetes therapy plus Cycloset

  • Usual Diabetes Therapy plus placeboDrug

    Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjects Experiencing Serious Adverse EventsTime frame: From baseline to week 52.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.